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Deficiency of the TLR4 analogue 
RP105 aggravates vein graft 
disease by inducing a pro-
inflammatory response
Anouk Wezel1,2,*, Margreet R. de Vries2,3,*, Johanna M. Maassen1, Peter Kip2, Erna A. Peters2,3, 
Jacco C. Karper2,3, Johan Kuiper1, Ilze Bot1,2 & Paul H. A. Quax2,3
Venous grafts are often used to bypass occlusive atherosclerotic lesions; however, poor patency leads 
to vein graft disease. Deficiency of TLR4, an inflammatory regulator, reduces vein graft disease. Here, 
we investigate the effects of the accessory molecule and TLR4 analogue RadioProtective 105 (RP105) 
on vein graft disease. RP105 deficiency resulted in a 90% increase in vein graft lesion area compared 
to controls. In a hypercholesterolemic setting (LDLr−/−/RP105−/− versus LDLr−/− mice), which is of 
importance as vein graft disease is usually characterized by excessive atherosclerosis, total lesion area 
was not affected. However we did observe an increased number of unstable lesions and intraplaque 
hemorrhage upon RP105 deficiency. In both setups, lesional macrophage content, and lesional CCL2 
was increased. In vitro, RP105−/− smooth muscle cells and mast cells secreted higher levels of CCL2. In 
conclusion, aggravated vein graft disease caused by RP105 deficiency results from an increased local 
inflammatory response.
Rupture of an atherosclerotic lesion with subsequent thrombus formation may lead to distal embolization of the 
blood vessel, resulting in adverse cardiovascular events1. Restoring blood flow to the ischemic tissue is therefore 
crucial, which can be accomplished by interventions such as placement of a (drug eluting) stent or a venous 
graft. Vein grafts are often used because of their long length, making it possible to bypass multiple atherosclerotic 
lesions, and their easy accessebility2–4. However, after ten years only an approximate 40% of the grafts is still pat-
ent5–8. It is thus of high importance to elucidate the mechanisms of vein graft disease and identify new therapeutic 
targets to prevent vein graft failure.
Excessive and uncontrolled smooth muscle cell (SMC) accumulation and proliferation result in the formation 
of intimal hyperplasia9. This process is accompanied by leukocyte influx into the vessel wall, which aggravates 
the inflammatory process and leads to superimposed atherosclerosis. Late vein graft failure may eventually be the 
result of complete occlusion caused by intimal hyperplasia and accelerated atherosclerosis or rupture of the vein 
graft lesion10.
To study the complex mechanisms behind vein graft disease, as well as to explore possible treatment options, 
a previously described murine vein graft model has been used11. In this model, lesions display typical concentric 
hyperplasia as well as lesional disruptions with intraplaque hemorrhage, with high resemblance to the complex 
lesions present in human vein grafts. When vein grafts are placed in mice on a high cholesterol diet, superim-
posed atherosclerosis will add to the lesional burden, as illustrated by lipid depositions and foam cell accumula-
tion12. Taken together, excessive SMC proliferation, lipid accumulation and an enhanced inflammatory response 
seem to be causing vein graft disease. Highlighting the importance of vascular inflammation in vein graft disease, 
we have previously shown that local silencing of Toll like receptor 4 (TLR4) significantly reduces vessel wall 
thickening in these murine venous grafts13, rendering this pathway of interest for future therapeutic interventions.
TLR4 belongs to the TLR family, a type of pattern recognition receptors, capable of inducing potent inflamma-
tory signalling. A unique feature of TLR4, compared to other TLRs, is that is does not directly bind to its ligands, 
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but is dependent on the ligand binding adaptor molecule MD2 and co-receptor CD1414. An additional accessory 
molecule known to regulate TLR4 signalling is RadioProtective 105 (RP105). Similar to TLR4, the TLR4 analogue 
RP105 forms a complex with the adaptor molecule MD1, but in contrast, the RP105/MD1 complex does not have 
an intracellular Toll/interleukin 1 receptor (TIR) signalling domain15. Originally, RP105 was described as a B 
cell specific surface molecule, capable of enhancing cellular proliferation and activation15. However, RP105 was 
later on demonstrated to be expressed on the cell membrane of dendritic cells (DCs) and macrophages as well. 
In contrast to its role on the B cell, RP105 inhibits TLR4 mediated responses in DCs and macrophages, leading 
for instance to an aggravated inflammatory response after lipopolysaccharide (LPS) injection in RP105 deficient 
mice16.
Taking into account the profound regulatory effects of RP105 on TLR4, and the previous finding that TLR4 
signalling aggravates vein graft disease, it is compelling to investigate the role of RP105 in vein graft disease. 
Therefore, in the current study we used the murine vein graft model to establish whether RP105 deficiency affects 
lesion formation. We hypothesized that lack of RP105, via increased TLR4 signalling, will result in aggravated 
vein graft disease. Also, we aimed to determine how RP105 affects vein graft disease in a hypercholesterolemic 
setting with superimposed atherosclerosis.
Results
RP105−/− mice show aggravated vein graft lesion development. Vein grafts were placed in 
RP105−/− mice and control C57BL/6 mice to investigate the effect of RP105 deficiency on vein graft disease. 
Interestingly, lack of RP105 resulted in a 90% increased vein graft lesion area (Fig. 1a; P = 0.011). Plaque mor-
phology was further analysed by staining for macrophages, SMC and collagen. The percentage of lesional mac-
rophages was significantly increased in mice deficient for RP105 (Fig. 1b; P = 0.010), with a slight increase in both 
the relative M1 and M2 macrophage content as demonstrated by a MAC/3iNOS and a MAC3/CD206 staining 
(Supplemental Figure 2). No changes were observed in the percentage of SMC between the two groups (Fig. 1c). 
Picrosirius red staining revealed a significant reduction of collagen content in the lesions of RP105−/− mice com-
pared to control mice (Fig. 1d; P = 0.039), which indicates that the lesion may be more unstable. The absolute area 
of the individual staining are given in Supplemental Figure 3.
To further determine lesion stability, we analysed for plaque dissections. Dissections were defined as a fissure 
or connection between the lumen and part of the vessel wall, accompanied by the presence of erythrocytes and 
fibrin layers in the lesions. In RP105−/− mice, 3 out of 13 mice displayed plaque dissections, while 0 out of 11 
disruptions were observed in C57BL/6 mice.
LDLr−/−/RP105−/− mice display lesions with an unstable phenotype. Next, we investigated 
whether high-fat diet feeding would alter the effects of RP105 deficiency on vein graft disease. LDLr−/−/RP105−/− 
mice and LDLr−/− mice as controls received autologous vein grafts while fed a western-type diet for 4 weeks. 
No changes were detected in total body weight (LDLr−/−: 27.7 ± 0.7 g versus LDLr−/−/RP105−/−: 28.2 ± 0.5 
g, P = 0.38) or plasma total cholesterol levels (LDLr−/−: 1228 ± 68 mg/dL versus LDLr−/−/RP105−/− mice: 
1235 ± 82 mg/dL, P = 0.95) between the two groups. Furthermore, we did not observe significant differences 
between plasma VLDL/LDL cholesterol or HDL cholesterol (Supplementary Figure 4). In contrast to mice on 
chow diet, no changes in vein graft lesion area were observed in LDLr−/−/RP105−/− mice compared to control 
LDLr−/− mice (Fig. 2a; P = 0.173). Analysis of plaque morphology showed an increase in relative macrophage 
staining in lesions of LDLr−/−/RP105−/− mice compared to control (Fig. 2b; P = 0.002). Relative M1 macrophage 
content did not differ between the groups, but we observed an increase in the relative amount of CD206+ mac-
rophages in the LDLr−/−/RP105−/− lesions compared to control (Supplemental Figure 5). We did not observe 
a significant difference in SMC staining between LDLr−/−/RP105−/− mice and LDLr−/− controls (P = 0.069; 
Fig. 2c). Relative lesional collagen content was significantly reduced in RP105 mice (Fig. 2d; P = 0.039). Absolute 
staining areas are displayed in Supplemental Figure 6.
The total number of plaque dissections and intraplaque haemorrhages was profoundly increased in LDLr−/−/
RP105−/− mice compared to LDLr−/− control mice (LDLr−/− mice: 3 out of 12 mice; LDLr−/−/RP105−/−: 10 out 
of 12 mice; Fig. 3a; P = 0.012, Fisher’s exact test). Furthermore, the average length of the dissections was higher in 
the LDLr−/−/RP105−/− mice (Fig. 3b; P = 0.008).
Unaltered MMP expression in RP105 deficient macrophages. As we observed a reduced collagen 
content in the lesions of RP105 deficient mice, and matrix metalloproteinases (MMPs) are known for its involve-
ment in collagen homeostasis, we measured MMP expression in macrophages. However, no major changes were 
found in the expression of MMP2, MMP8 and MMP9 as well as in the expression of TIMP1, TIMP2 and TIMP3 
at baseline or after stimulation with a concentration range of LPS in RP105−/− macrophages compared to control 
(Supplemental Figure 7).
Macrophage proliferation in vitro and in vivo. Monocyte migration was recently established to be ham-
pered upon RP105 deficiency in an atherosclerotic setting17. To elucidate the mechanisms behind the increased 
percentage of lesional macrophages observed in both in vivo studies, we thus aimed to determine macrophage 
proliferation, since it has recently been described that local macrophage proliferation may add to the lesional bur-
den18. Peritoneal macrophages isolated from LDLr−/−/RP105−/− mice, which are under the influence of a variety 
of proliferative stimuli in vivo, showed an increased expression of the cellular proliferation marker Ki67 compared 
to peritoneal macrophages isolated from LDLr−/− mice (Fig. 4a). Also in the vein graft lesions of RP105−/− mice, 
the number of Ki67+ macrophages (as illustrated in Fig. 4b) tended to be increased as compared to control vein 
grafts (P = 0.06, Fig. 4c). Although less pronounced, macrophage proliferation also seemed enhanced in the 
LDLr−/−/RP105−/− lesions as compared to LDLr−/− lesions (Fig. 4e). Taken together, these data demonstrate that 
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RP105 deficient macrophages, under inflammatory conditions, are able to proliferate at a higher rate as compared 
to control macrophages.
RP105−/− SMC produce increased levels of CCL2. To further examine why we observe the increased 
percentage of lesional macrophages in RP105 deficient mice, we determined CCL2 secretion in vitro, which is 
known to be one of the key chemokines involved in monocyte recruitment to the lesion19. Since the SMC is one 
of the major determinants of vein graft disease, we investigated whether SMC deficient in RP105 produce altered 
levels of CCL2. Indeed, primary cultured SMC lacking RP105 were seen to secrete significantly increased CCL2 
amounts after stimulation with LPS, compared to control SMC (Fig. 5a; P = 0.0001). IL-6 secretion from vSMCs 
lacking RP105 was reduced as compared to control v SMCs (Fig. 5b; P = 0.0005), while TNFα secretion was not 
detectable under these conditions. Of note, RP105 deficiency did not alter release of CCL2, IL-6 or TNFα from 
macrophages (Supplemental Figure 8).
RP105 deficiency aggravates mast cell activation. In addition to the SMC, we have previously shown 
that mast cells also play a key role in vein graft disease20. Moreover, mast cells can contribute to plaque destabi-
lization, for instance via the degradation of collagen by mast cell derived tryptase and chymase21,22. Therefore, 
we aimed to determine the relevance of RP105 in mast cell function. First, we analysed whether cultured 
mast cells express RP105, which is indeed the case at both mRNA and protein level (Supplemental Figure 9). 
Next, we examined whether RP105 plays a functional role in mast cell activation by culturing bone marrow 
derived mast cells from RP105 deficient mice and control mice. Mast cells were stimulated with 10 ng/mL and 
Figure 1. RP105 deficiency aggravates vein graft disease. Vein graft lesion area was significantly increased in 
RP105−/− mice compared to control C57BL/6 mice (a). The macrophage content, expressed as the percentage 
of stained area in the intimal hyperplasia, was higher in RP105−/− mice compared to control (b), while no 
changes were found in the percentage of smooth muscle cells (ASMA, alpha-smooth muscle cell actin, (c). 
Collagen content was decreased in RP105−/− mice, indicative of less stable lesions (d). The micrographs 
show representative images of each group (50x). N = 11 C57BL/6 mice/group, N = 13 RP105−/− mice/group. 
*P < 0.05.
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100 ng/mL LPS for 4 and 24 hours. RP105 deficient mast cells were seen to secrete higher levels of IL-6 and TNFα 
compared to control mast cells, which was dose-dependently increased after 4 hours of LPS activation (Fig. 5c,d). 
Also, CCL2 secretion of RP105−/− mast cells was highly increased compared to control mast cells, which may also 
have contributed to the increased lesional macrophages in vivo (Fig. 5e). Furthermore, 24 hours of activation still 
showed a significant increase in IL-6 and CCL2 production of RP105−/− mast cells compared to control. These 
data indicate that RP105 deficiency on the mast cell results in increased activation and cytokine release.
We then investigated whether cellular proliferation is altered in RP105 deficient mast cells. Interestingly, 
RP105 deficient mast cells show an increased proliferation rate compared to control mast cells under basal con-
ditions (Fig. 5f).
Since we observed an increased activation status of RP105−/− mast cells, and mast cells are known to secrete 
a variety of growth factors, we assessed whether the releasate of activated RP105−/− mast cells has differential 
effects on macrophages compared to control mast cells. Indeed, after adding supernatant of RP105−/− mast cells 
to macrophages, we observed an increased proliferation of macrophages compared to the addition of supernatant 
from control mast cells (Fig. 5g).
Increased perivascular mast cell numbers and activation status in vivo. Considering the profound 
effects of RP105 deficiency on the mast cell found in vitro, we aimed to determine whether mast cell numbers and 
activation status in vivo are altered as well. Indeed, the average number of peri-adventitial mast cells was increased 
Figure 2. Lesion size and plaque morphology in LDLr−/−/RP105−/− mice on a western type diet. No 
changes were observed in the vessel wall area of LDLr−/−/RP105−/− mice compared to control LDLr−/− mice (a). 
Similar to mice fed a chow diet, a higher percentage of macrophages was observed in LDLr−/−/RP105−/− (b). 
Smooth muscle cell content was unaltered between the two groups (ASMA, (c)) and again a decrease in lesional 
collagen was observed (d). N = 12 LDLr−/− mice/group. N = 12 LDLr−/−/RP105−/− mice/group. *P < 0.05, 
**P < 0.01.
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in RP105−/− mice compared to control mice (Fig. 6a; P = 0.009). Moreover, in RP105−/− mice the average number 
of activated mast cells was significantly higher (Fig. 6b; P = 0.033, Supplemental Figure 10).
In LDLr−/− mice, basal mast cells levels were increased already upon western type diet feeding compared to 
C57BL/6 controls, which was further increased in mice lacking RP105, however this did not reach significance 
(Fig. 6c; P = 0.062). Also, the number of activated mast cells showed a trend towards an increase in LDLr−/−/
RP105−/− mice compared to control (Fig. 6d; P = 0.057).
Figure 3. Increased plaque dissections in LDLr−/−/RP105−/− mice. The number of plaque dissections in 
LDLr−/−/RP105−/− mice was significantly higher compared to control LDLr−/− mice (a). Also, the total length 
of plaque dissections was increased in LDLr−/−/RP105−/− mice compared to control (b). The micrographs show 
representative images of each group 50x. N = 12 LDLr−/− mice/group. N = 12 LDLr−/−/RP105−/− mice/group. 
*P < 0.05.
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Increased CCL2 expression in vivo. Taking into consideration the increased amount of CCL2 secreted 
in vitro by both RP105 deficient SMC and mast cells, we aimed to determine whether lesional CCL2 expression 
was increased in RP105−/− mice as well. Intriguingly, the CCL2 positive area in the lesions was significantly 
increased in RP105−/− mice compared to control mice (Fig. 7a; P = 0.002). Also, the lesional CCL2 positive area 
in hypercholesterolemic LDLr−/−/RP105−/− mice was profoundly increased compared to control mice (Fig. 7b; 
P = 0.0001). The higher expression of CCL2 in vein graft lesions of RP105 deficient mice may thus explain the 
increased macrophage content observed in these lesions. The expression of lesional CCR2, the receptor for CCL2 
remained unaltered in both experimental groups (Fig. 7c,d).
Discussion
In the current study we demonstrate that lack of the regulatory molecule RP105 results in a marked increase in 
vein graft lesion area. Furthermore, we show that in a hypercholesterolemic setting, RP105−/− lesions display an 
increase in plaque dissections and plaque destabilization.
In our study, when comparing the C57Bl/6 and LDLr−/− control groups, we observed an increase in lesion 
development upon high cholesterol feeding, which was, as described previously, caused by enhanced macrophage 
infiltration and collagen content, but also of lipid deposition in the plaque13. In a normocholesterolemic setup, 
RP105 deficiency resulted in an increase in vein graft disease mainly due to an increase in macrophage con-
tent, while lesion growth was similar between control and RP105 deficient mice under hypercholesterolemic 
conditions. We therefore postulate that RP105 deficiency in LDLr−/− mice does not have an additive effect on 
lesion growth, because that is already highly induced by the increase in plasma cholesterol. Despite the lack of 
effects on lesion size in that study, we observed prominent effects of RP105 deficiency on lesion morphology as 
demonstrated by an increase in macrophage content, illustrative of an enhanced inflammatory response, and a 
decrease in collagen content, which gives rise to the stability of the lesion. More evident even was the increase in 
the number of plaque dissections, which is, as previously described12, a prominent marker for plaque instability 
in this vein graft model. Taken together, we thus conclude that RP105 deficiency in hypercholesterolemia results 
in reduced plaque stability as compared to the controls. In fact, in both studies decreased lesional collagen content 
Figure 4. Macrophage proliferation. Peritoneal macrophages isolated from LDLr−/−/RP105−/− mice showed 
an increased expression of the cellular proliferation marker Ki67 compared to peritoneal macrophages isolated 
from LDLr−/− mice (a), *P < 0.05). Intraplaque macrophage proliferation tended to be increased in RP105−/− 
compared to C57Bl/6 mice (P = 0.06) as demonstrated by a MAC3/Ki67 double staining (b) (right micrographs, 
N = 11 C57BL/6 mice/group, N = 13 RP105−/− mice/group). No significant differences could be detected in 
lesional macrophage proliferation between LDLr−/− and LDLr−/−/RP105−/− mice (c). N = 12 LDLr−/− mice/
group. N = 12 LDLr−/−/RP105−/− mice/group.
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was observed, while the macrophage content was enhanced. Our in vitro data demonstrate that RP105 deficient 
SMC as well as RP105−/− mast cells secrete excessive levels of CCL2 compared to control cells, which may con-
tribute to the increase of macrophages in the plaque. Also, local macrophage proliferation may be at least partly 
responsible for the increased macrophage content. Moreover, we are the first to demonstrate that RP105 plays a 
functional role in mast cell activation and proliferation, possibly aggravating lesion destabilization.
Mast cells are potent inflammatory cells which have previously been implicated in vein graft disease and 
plaque destabilization20–23. In those studies, mast cell deficiency led to reduced intimal hyperplasia, while acti-
vation of mast cells upon vein graft placement resulted in increased disease development20, thus establishing the 
importance of this cell type in vein graft disease. Mast cells exert their detrimental effects through the secretion 
of specific proteases and a variety of cytokines and chemokines, which all contribute to increased inflamma-
tion24. Activation of mast cells may be induced by a range of mediators such as IgE, neuropeptides25, comple-
ment factors20 or via toll like receptors, in particular TLR426. Whether TLR4 signalling may actually lead to mast 
cell degranulation is still under debate, however, it is well established that TLR4 activation results in increased 
cytokine secretion27. RP105 is known to inhibit TLR4 signalling in macrophages and dendritic cells, however 
up to date evidence describing a role for RP105 in mast cells is lacking. Here, we have established that bone nar-
row derived mast cells express RP105 and as described previously, LPS dose-dependently increased the release 
of CCL2, IL-6 and TNFα by control mast cells. Interestingly, this increase was significantly higher in RP105 
deficient mast cells, indicating that these cells, upon activation, secrete excessive amounts of cytokines in its 
surroundings. We now show that also on the mast cell, RP105 has an inhibitory effect and consequently, lack of 
Figure 5. Effect of RP105 deficiency on smooth muscle cell and mast cell function. After 24 hours 
stimulation with 1 and 3 ng/mL LPS, RP105−/− vascular smooth muscle cells (v SMCs) secrete dose-dependent 
increased levels of CCL2 (a), which was significantly higher compared to control v SMCs (N = 4). IL-6 secretion 
was significantly reduced in RP105−/− v SMCs (b). ***P < 0.001 compared to control v SMCs. ###P < 0.001 
compared to unstimulated v SMCs, nd =  not detectable. After 4 hours stimulation with 10 ng/mL and 100 ng/
mL LPS, bone marrow derived RP105−/− mast cells secreted dose-dependently increased levels of IL6 (c), TNFα 
(d) and CCL2 (e), which was significantly higher compared to control mast cells (N = 3, typical example of 
multiple experiments). The basal proliferation rate of RP105−/− mast cells was significantly higher compared to 
control mast cells (f) (N = 4). Addition of the supernatant from RP105−/− mast cells to macrophages resulted in 
increased proliferation compared to the addition of supernatant from control mast cells (g) (N = 4). *P < 0.05. 
***P < 0.001 compared to control mast cells. #P < 0.05, ###P < 0.001 compared to unstimulated mast cells.
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RP105 leads to increased activation. Therefore, we postulate that the increase in vessel wall thickening observed 
in RP105−/− mice on a chow diet may at least partly be caused by aggravated mast cell activation. Also, mast cell 
derived tryptase and chymase have previously been shown to increase collagen degradation22, which thus may 
have contributed to the decreased lesional collagen content observed in the current study.
In LDLr−/−/RP105−/− mice fed a western type diet, we observed a decrease in collagen content as well, and 
an increase in plaque dissections, which was however accompanied by a less pronounced effect on mast cell 
activation. We have previously established that upon western type diet feeding, vascular mast cell numbers are 
enhanced22. Indeed, control LDLr−/− mice fed a western type diet already displayed higher numbers of activated 
mast cells, compared to control C57BL/6 mice on a chow diet. Therefore, the additive inflammatory effect of 
RP105 deficiency on mast cells in mice receiving a high cholesterol diet may be less evident. Nevertheless, RP105 
deficiency in a hypercholesterolemic setting resulted in a severe decrease in plaque stability, thus establishing a 
critical role for RP105 in maintaining vein graft integrity.
Previously, we have investigated the effects of RP105 in other mouse models of vascular remodelling as well. 
Besides vein graft surgery, balloon angioplasty with stent placement is used for the treatment of atherosclerosis; 
however in-stent restenosis impairs the success rate of this operation28. In a murine mouse model for reste-
nosis we have shown that RP105 deficiency results in increased neo-intima formation29, which is in line with 
the observed effects on vein graft disease in the current study. In that study, overexpression of soluble RP105 
in complex with MD1 inhibited neointima formation, while single RP105 or MD1 were ineffective, suggesting 
that the soluble RP105-MD1 complex is therapeutically relevant for vein graft disease as well. Conversely, in 
a setting of atherosclerosis, mice on a western type diet lacking RP105 on their myeloid cells develop reduced 
atherosclerotic lesions due to changes in B cells30. Also, total body RP105 deficiency was seen to reduce ath-
erosclerosis and decrease lesional macrophage content, caused by a reduced monocyte influx17. These distur-
bances in monocyte migration were also observed in RP105−/− mice with hind limb ischemia31. The fact that 
we observe an increase in lesional macrophages may be explained by the profound increase in CCL2 secretion 
by both RP105−/− SMC and mast cells, which could have resulted increased monocyte recruitment to the lesion 
in vivo. As vein graft lesions are highly enriched in SMC compared to atherosclerotic plaques, the effect of SMC 
derived products, such as CCL2, may be more prominent in vein graft disease as compared to atherosclerosis. We 
have previously shown that the CCR2-CCL2 axis is of vital importance for the development of vein graft disease, 
as inhibition of this specific chemokine receptor-ligand interaction, by either a specific antagonist32 or a shRNA 
targeting CCR233, effectively inhibited intimal hyperplasia. In this study, CCL2 expression in the vein graft lesions 
of mice deficient for RP105 was significantly increased compared to controls, which can, at least partly, explain 
Figure 6. In vivo mast cell activation. The amount of perivascular mast cells was markedly increased in the 
perivascular tissue from vein grafts of RP105 deficient mice compared to control C57BL/6 mice (a). Also, the 
number of activated mast cells was significantly higher in RP105−/− mice (b). Mast cell numbers, as well as the 
amount of activated mast cells, showed a trend towards an increase in LDLr−/−/RP105−/− mice fed a western 
type diet compared to LDLr−/− mice (c,d). N = 11 C57BL/6 mice/group, N = 13 RP105−/− mice/group, N = 12 
LDLr−/− mice/group. N = 12 LDLr−/−/RP105−/− mice/group. (1000x). *P < 0.05. **P < 0.01.
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the increase in macrophage content and plaque progression. Macrophage polarization did not seem to be largely 
affected in vivo, as we observed similar to slightly higher levels of both M1 and M2 macrophages in lesions 
of RP105 deficient animals. Under hyperlipidemic condition, M2 macrophage levels were somewhat increased, 
but in lesions of both the control and RP105 deficient mice the number of M1 macrophages highly exceeds the 
amount of M2 macrophages, rendering an anti-inflammatory and plaque resolving activity of these relatively few 
macrophages unlikely. Also in vitro, cytokine secretion did not differ between macrophages derived from control 
or RP105deficient mice, suggesting that RP105 does not directly affect macrophage polarization.
RP105 has also been implicated in the induction of apoptosis. Literature regarding RP105-mediated effects 
on apoptosis are however rather contradictory, and seem to largely depend on cell type investigated. It has for 
example been shown that RP105 protects against apoptosis in cardiomyocytes34, but it has also been established 
that an anti-RP105 antibody can rescue B cells from apoptosis35. We have previously established that the amount 
of apoptotic cells in vein graft lesions is very low (~2% of the total amount of cells)36, and therefore we regard 
it unlikely that a further reduction in the already low amount of apoptosis will lead to the observed increase in 
intraplaque macrophages upon RP105 deficiency. Finally, we observed that macrophages of RP105−/− mice tend 
to have an increased proliferation rate as compared to control macrophages under inflammatory conditions. 
Macrophage proliferation in atherosclerotic plaques has been described previously18, and in our study this phe-
nomenon may be another contributing mechanism to the observed increase in lesion macrophage content. The 
contrasting effects of RP105 seen in this and previous studies on spontaneous atherosclerosis highlight the dif-
ference in underlying mechanisms of diet-induced atherosclerotic lesion development versus restenosis and vein 
graft disease, the latter two in which smooth muscle cells play a dominant role.
Figure 7. In vivo CCL2 and CCR2 staining. Immunohistochemical stainings revealed a significant increase in 
the CCL2 positive area in the lesions of RP105−/− mice compared to control C57BL/6 mice (a). Also, the lesional 
CCL2 area was profoundly increased in hypercholesterolemic LDLr−/−/RP105−/− mice compared to control 
LDLr−/− mice (c). No differences were observed in lesional CCR2 expression between both experimental 
groups (b,d). N = 11 C57BL/6 mice/group, N = 13 RP105−/− mice/group, N = 12 LDLr−/− mice/group. N = 12 
LDLr−/−/RP105−/− mice/group. **P < 0.01.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:24248 | DOI: 10.1038/srep24248
In summary, the current study is the first to demonstrate that lack of RP105 results in increased lesion area 
in murine vein grafts. In a hypercholesterolemic setting, RP105 deficiency resulted in an increase in lesion dest-
abilization and a higher number of plaque dissections accompanied by intraplaque hemorrhage. In vitro studies 
suggest that this may be caused by excessive CCL2 secretion by RP105−/− SMC, increased recruitment and pro-
liferation of RP105−/− monocytes and macrophages, as well as by an increased inflammatory and proliferative 
phenotype of RP105−/− mast cells.
Material and methods
Mice. All animal experiments were approved by the animal welfare committee of the Leiden University 
Medical Center (approval reference number 09098 and 12153). This study was performed in compliance with 
Dutch government guidelines and the Directive 2010/63/EU of the European Parliament. RP105−/− mice 
were kindly provided by K. Miyake (Tokyo University, Japan) and were described previously16. Male wild type 
(WT, C57BL/6, 10–12 weeks old) (n = 11) and RP105−/− animals (C57BL/6 background, backcrossed for more 
than 10 generations, 10–12 weeks old) (n = 13) were bred in our facility at the Leiden University Medical Center 
(Leiden, The Netherlands) and during the experiment, mice were given water and chow ad libitum.
To study the effects of RP105 deficiency on vein graft disease in a hyperlipidemic setting, male LDLr−/− mice 
(n = 12, 12–16 weeks old) and male LDLr−/−/RP105−/− mice (n = 12, 12–16 weeks old) were used. Mice were 
fed a western-type diet containing 0.25% cholesterol and 15% cacaobutter (SDS) for 4 weeks. Plasma total cho-
lesterol levels were measured by enzymatic procedures using precipath standardized serum as an internal stand-
ard (Boehringer Mannheim). The distribution of cholesterol among the different lipoproteins was determined 
by loading 30 μL serum onto a Superose 6 column (3.2 × 30 mm; Smart-system, GE Healthcare). Serum was 
fractionated at a constant flow rate of 50 μL/min with PBS. Total cholesterol in the effluent were determined 
enzymatically.
Surgical intervention. Before surgery and sacrifice, mice were anesthetized by an intra-peritoneal injec-
tion with Midazolam (5 mg/kg, Roche), Dexdomitor (0.5 mg/kg, AST Farma) and fentanyl (0.05 mg/kg, Janssen). 
Adequacy of anaesthesia was monitored by regular visual inspection and toe pinch reflex. After surgery mice were 
antagonized with a subcutaneous injection of flumazenil (0.5 mg/kg, Fresenius Kabi,) and Antisedan (2.5 mg/kg, 
AST farma). Buprenorphine (0.1 mg/kg, MSD animal Health) was given after surgery to relieve pain. Vein graft 
surgery was performed in order to induce intimal hyperplasia in the venous grafts11. In brief, the carotid artery 
of the recipient mice was cut in the middle; both ends of the artery were everted around cuffs and ligated with 
8.0 sutures. Donor littermates were anesthetized as described above, after which the vena cava was harvested and 
donor mice were exsanguinated. The vena cava was then sleeved over the cuffs in the recipient mice. At sacrifice 
after 28 days, mice were exsanguinated via orbital bleeding. Vein grafts were harvested and fixated in 4% formal-
dehyde, dehydrated and paraffin-embedded for histology.
Histological and immunohistochemical analysis. All (immuno)-histochemical stainings and measure-
ments were performed on six consecutive cross-sections, approximately 150 μm interspaced, of paraffin embed-
ded vein grafts segments (5 μm thick). Hematoxylin-phloxine saffron (HPS) staining and Masson trichrome 
stainings were used for the measurement of vein graft lesion area and plaque dissection analysis, while collagen 
content was visualized with a picrosirius red staining under polarized light. Composition of the vein graft lesions 
was further evaluated by staining for macrophages (MAC3, BD-Pharmingen 550292), smooth muscle cell actin 
(Sigma; 1A4), CCL2 ((Novus Biologicals, NBD1-42280) and CCR2 (Abcam; ab222324). M1 macrophages were 
identified using a MAC3/iNOS (iNOS, Novus Biologicals; NB300-605) double staining, whereas M2 macrophages 
were visualized with a MAC3/CD206 (Abcam; ab64693) double staining. Intraplaque macrophage proliferation 
was determined by staining sections for MAC3 and the proliferation marker Ki67 (Abcam; ab16667). Double 
stained slides were scanned with a digital slide scanner (Pannoramic 250 Flash, 3DHistech Ltd). Double posi-
tive MAC3/Ki67 cells were counted manually, whereas MAC3/iNOS (M1 macrophages) and MAC3/CD206 (M2 
macrophages) positive cells were scored semi quantitative using the following system for each of the macrophages 
subset (0: no double staining, 1: <10% of macrophages were positive for the individual M1 or M2 marker, 2: 
> 10% < 20% MAC3/iNOS+ or MAC3/CD206+ cells, 3: > 20% MAC3/iNOS+ or MAC3/CD206+ cells). 
Mast cells were histochemically stained using an enzymatic chloroacetate esterase kit (Sigma-Aldrich) and their 
numbers were microscopically counted. A mast cell was considered resting when all granules were maintained 
inside the cell; when granules were apparent in the vicinity of the mast cell they were scored as activated. Plaque 
dissection analysis was performed over a total vein graft length of 1800 μm. Disruptions were defined as a con-
nection or fissure between the lumen and part of the vessel wall underneath the adventitia, filled with fibrin 
and erythrocytes11. Quantification of the lesion area and immunostained positive area were performed using 
computer assisted software (Leica Qwin, Leica). In brief, the total intimal area was measured, as well as the 
stained area within the intimal area. The stained area was than calculated as a percentage of the total intimal area. 
Negative control stainings are given in Supplemental Figure 1, establishing the specificity of the used antibodies. 
All measurements were performed in a blinded manner by a single observer.
Cell culture. LDLr−/− and LDLr−/−/RP105−/− mice were anaesthetized as described above and sacrificed via 
cervical dislocation, after which bone marrow (BM) suspensions were isolated by flushing the femurs and tibias 
with PBS. BM derived mast cells (BMMCs) were grown by culturing BM cells from LDLr−/− mice and LDLr−/−/
RP105−/− mice at a density of 0.25*106 cells in RPMI containing 10% fetal bovine serum (FBS), 2 mmol/L 
l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin (all from PAA) and mIL3 supernatant (supernatant 
from WEHI cells overexpressing murine Interleukin (IL)-3) for 4 weeks. RAW 264.7 cells (a murine macrophage 
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cell line) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Fetal Calf ’s 
Serum (FCS), 2 mmol/L L-glutamine, 100 U/mL penicillin and 100ug/mL streptomycin.
To generate bone marrow derived macrophages (BMDM), cells from bone marrow of LDLr−/− mice and 
LDLr−/−/RP105−/− mice were cultured for 7 days in RPMI medium supplemented with 20% fetal calf serum 
(FCS), 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin (all from PAA) and 30% L929 
cell-conditioned medium (as the source of macrophage colony-stimulating factor (M-CSF)) in petridishes 
(Greiner Bio-one)37.
Murine v SMCs explanted from aortas of RP105−/− mice and control mice (anesthetized as described above 
and sacrificed via asphyxiation) were cultured and incubated overnight with either LPS (1 ng/mL or 3 ng/mL) or 
control medium (n = 4) in 0.2% FBS. IL-6, TNFα and CCL2 ELISAs were performed according to manufacturer’s 
protocol (BD Biosciences).
Macrophage activation. Bone marrow derived LDLr−/− and LDLr−/−/RP105−/− macrophages cultured as 
described above, were activated with 1 ng/mL, 10 ng/mL or 50 ng/mL LPS (from E. Coli, Sigma-Aldrich) for 
4 hours (n = 3) at a density of 106 cells per well. Cells were then spun down (1500 rpm, 5 minutes) and used 
for RNA isolation. Supernatant was used to measure cytokine secretion by ELISA according to manufacturer’s 
protocol.
Proliferation assay. To measure the effect of RP105 on macrophage proliferation, LDLr−/−/RP105−/− 
BMDM and control LDLr−/− BMDM were seeded at a density of 4*104 cells per well (n = 4). Cells were incubated 
overnight with 0.5 μCi [3H]thymidine (PerkinElmer) per well at 37 °C. [3H]Thymidine incorporation was quanti-
fied in a liquid scintillation analyser (Packard 1500 Tricarb,).
To investigate the effect of RP105 deficiency on mast cell proliferation, LDLr−/− and LDLr−/−/RP105−/− 
BMMCs were seeded at a density of 104 cells per well. Cells were incubated overnight with 0.5 μCi [3H]thymidine 
(PerkinElmer) per well. [3H]Thymidine incorporation was measured as described above. The effect of RP105−/− 
mast cell supernatant on macrophages proliferation was investigated by seeding RAW cells at a density of 4*104 
cells per well. The next day, cells were exposed to supernatant of non-activated LDLr−/− or LDLr−/−/RP105−/− 
mast cells (n = 4). After overnight incubation 0.5 μCi [3H]thymidine (PerkinElmer), proliferation was measured 
as described above.
To measure macrophage proliferation in an in vivo setting, peritoneal macrophages were isolated from 
LDLr−/− and LDLr−/−/RP105−/− mice (anaesthetized as described above and sacrificed via cervical disloca-
tion) by lavage of the peritoneal cavity with PBS (10 mL). Expression of the surface markers CD11b (CD11b-PE, 
Ebioscience, 12-0112-82), F4/80 (F4/80-APC, Ebioscience, 17-4801-82) and the proliferation marker Ki67 
(KI67-FITC, Ebioscience, 11-5698-82) was determined by means of FACS analysis (FACS Canto, BD Biosciences).
Mast cell activation. LDLr−/− and LDLr−/−/RP105−/− BMMCs were seeded at a density of 106 cells per well 
(n = 3), after which they were stimulated with 1 ng/mL, 10 ng/mL or 100 ng/mL LPS (from E. Coli, Sigma-Aldrich, 
St. Louis, MO, USA). After 4 hours and 24 hours activation, cells were spun down (1500 rpm, 5 minutes) and 
the supernatant was collected for further analysis. ELISAs were performed according to manufacturer’s pro-
tocol. Expression of the surface markers RP105 (RP105-PE, Ebioscience, 12-1801-81) and TLR4 (TLR4-APC, 
Ebioscience, 12-9924-82) on control LDLr−/− mast cells was determined by means of FACS analysis.
RNA isolation, cDNA synthesis and qPCR. Guanidine thiocyanate (GTC) was used to extract total RNA 
from BMMCs and BMDMs38. RNA was reverse transcribed by M-MuLV reverse transcriptase (RevertAid, MBI 
Fermentas) and used for quantitative analysis of mouse genes (Supplemental Table 1) with an ABI PRISM 7700 
Taqman apparatus (Applied Biosystems). Murine hypoxanthine phosphoribosyltransferase (HPRT) and murine 
ribosomal protein 27 (RPL27) were used as standard housekeeping genes.
Statistical analysis. All data are presented as mean ± SEM. A 2-tailed Student’s t-test was used to compare 
individual groups. When comparing more than 2 groups, a 2-way ANOVA was performed with a Bonferroni 
post-test. Non-Gaussian distributed data were analysed using a two-tailed Mann-Whitney U test. Frequency 
data analysis was performed by means of the Fisher’s exact test. A P-level of < 0.05 was considered statistical 
significant.
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